Clinical trials: sponsored by Novartis Pharmaceuticals
Multiple Sclerosis
WOE of Anti-CD20 Therapies
The nature, intensity, and prevalence of this wearing-off effect remain poorly understood. To our knowledge, there is no consensus in the literature on what symptoms constitute a wearing-off effect, nor is there a single…
- Trial name
- NCT06121349
- Testing
- ocrelizumab, ofatumumab
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Novartis Pharmaceuticals
Hepatic Impairment
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
The main purpose of this study is to evaluate the effect of varying degrees of impaired hepatic function (by Child Pugh classification) on the plasma PK of siremadlin after a single oral dose.
- Trial name
- NCT05599932
- Testing
- Siremadlin
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf
This is a retrospective and prospective, observational mixed-methods (quantitative and qualitative) cohort study of patients who are treated with either Ofatumumab or Ocrelizumab that will be recruited and followed up for one…
- Trial name
- NCT05266469
- Testing
- Ofatumumab, Ocrelizumab
- Where
- 6 sites in United Arab Emirates
- Volunteers
- 168 people
- Sponsor
- Novartis Pharmaceuticals
Retinopathy of Prematurity
Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity
This study was an open-labeled, multicenter, single arm, observational post-marketing surveillance study under routine clinical practice with no mandated treatments, visits or assessments.
- Trial name
- NCT05304949
- Testing
- Lucentis
- Where
- 6 sites in South Korea
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia
A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients
This was a retrospective, cross-sectional, center-based chart review study that collected real-world data for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients receiving tisagenlecleucel (tisa-cel).
- Trial name
- KareALL (NCT07039383)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum
Health-related Quality of Life, Symptom Severity, and Pain Among Patients With PIK3CA-related Overgrowth Spectrum: A Mixed-methods Observational Study
This was a mixed-methods observational study that incorporated both qualitative interviews and longitudinal quantitative data collection through an online survey (initial, 2 months, and 4 months).
- Trial name
- NCT05294289
- Testing
- Alpelisib
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
C3 Glomerulopathy
Home Reported Outcomes in C3G Study
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall Health-related Quality of Life (HRQoL) experienced by C3 glomerulopathy (C3G) patients and their caregivers.
- Trial name
- NCT07029542
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Food Hypersensitivity, Anaphylaxis
A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis
This was a retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel).
- Trial name
- NCT07027163
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Patterns of Inclisiran Use in the Real World: An Analysis of US Databases
This was a retrospective observational cohort study of patients who initiated inclisiran, alirocumab, or evolocumab in a real-world setting in the United States.
- Trial name
- NCT07023445
- Where
- United States
- Volunteers
- 37,688 people
- Sponsor
- Novartis Pharmaceuticals
Immunoglobulin A Nephropathy
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
- Trial name
- NCT06952426
- Testing
- No intervention, Other treatment, Iptacopan
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
This was a primary data collection-based observational special drug-use surveillance to be conducted in accordance with the Good Post-marketing Study Practice (GPSP) ordinance.
- Trial name
- NCT05526729
- Testing
- Beovu
- Where
- 76 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer, BRAF Mutant Colorectal Cancer
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
The primary purpose of this study was to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that had progressed despite…
- Conditions
- Pancreatic Cancer, BRAF Mutant Colorectal Cancer, Melanoma, Triple Negative Breast Cancer
- Trial name
- NCT01351103
- Testing
- LGK974, PDR001
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Vulgaris, Psoriatic Arthritis
Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP
This was a multicenter, centrally registered observational study without a control group. This observational study was a specified drug use-results survey conducted under GPSP to collect information on safety and efficacy during…
- Conditions
- Psoriasis Vulgaris, Psoriatic Arthritis, Pustular Psoriasis
- Trial name
- NCT05215561
- Testing
- Cosentyx
- Where
- 21 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
This will be a multicenter, national, non-interventional, prospective cohort study
- Conditions
- Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Follicular Lymphoma
- Trial name
- NCT05541341
- Testing
- tisagenlecleucel
- Where
- 7 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib
This was a multinational, non-interventional, cross-sectional survey conducted among HCPs based in the EU/EEA who prescribe Piqray.
- Trial name
- NCT05073120
- Testing
- Piqray Prescriber's/HCP guide for hyperglycemia
- Where
- Switzerland
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Anemia, Aplastic
Real-world Outcomes of Aplastic Anemia Patients Treated With Eltrombopag: A Medical Claims Database Study
The main goal of this study was to investigate the effectiveness and safety of eltrombopag (ETB) when compared to other treatments in Japanese aplastic anemia (AA) patients using data from the Medical Data Vision (MDV)…
- Trial name
- NCT06991894
- Where
- United States
- Volunteers
- 2,517 people
- Sponsor
- Novartis Pharmaceuticals
Triple Negative Breast Cancer (TNBC)
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
This is a Phase Ib, open label, dose escalation study of spartalizumab + LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab, followed by a dose expansion in adult patients with advanced or metastatic TNBC.
- Trial name
- NCT03742349
- Testing
- spartalizumab, LAG525, NIR178
- Where
- 13 sites in United States, Australia and 7 more
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
This was an open-label, multi-center, FIH study with a single ascending dose (SAD) design that assessed the safety, tolerability and pharmacokinetics (PK) of a single IVT dose of MHU650 in up to 24 participants with macular edema.
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
- Trial name
- NCT04635800
- Testing
- MHU650
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Leukemia, Myeloid
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine or azacitidine in AML and intermediate or high- risk MDS patients…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
- Trial name
- NCT03066648
- Testing
- Decitabine, PDR001, MBG453
- Where
- 11 sites in United States, Australia and 6 more
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
The primary objective of the trial was to characterize the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose (RD) for expansion of single agent KAZ954 and KAZ954 in combination with PDR001, NIR178 and NZV930.
- Trial name
- NCT04237649
- Testing
- KAZ954, PDR001, NIR178
- Where
- 13 sites in United States, Canada and 6 more
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.